Provectus Biopharmaceuticals Announces Oral Presentation of Updated Study Data from Phase 1…
Provectus Biopharmaceuticals Inc.KNOXVILLE, TN, March 16, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of investigational cancer immunotherapy PV-10 (rose bengal sodium) for the…